2026-08-29T14:17:39Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/181492024-11-28T14:58:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Alba-Bernal, Alfonso author Lavado-Valenzuela, Rocío author Domínguez-Recio, María Emilia author Jiménez-Rodriguez, Begoña author Queipo-Ortuño, María Isabel author Alba, Emilio author Comino-Méndez, Iñaki author 2020-11-09 Breast cancer is the most common cancer type in women worldwide and its early detection is crucial to curing the disease. Tissue biopsy, currently the method of choice to obtain tumour molecular information, is invasive and might be affected by tumour heterogeneity rendering it incapable to portray the complete molecular picture. Liquid biopsy permits to study disease features in a more comprehensive manner by sampling biofluids and extracting tumour components such as circulating-tumour DNA (ctDNA), circulating-tumour cells (CTCs), and/or circulating-tumour RNA (ctRNA) amongst others in a monitoring-compatible manner. In this review, we describe the recent progress in the utilization of the circulating tumour components using early breast cancer samples. We review the most important analytes and technologies employed for their study. 10.1016/j.ebiom.2020.103100 2352-3964 EBioMedicine http://hdl.handle.net/10668/3766 33161226 http://hdl.handle.net/20.500.12105/18149 Liquid biopsy Localized breast cancer Circulating-tumour DNA Circulating-tumour cells Circulating-tumour RNA Biopsia líquida Neoplasias de la mama ARN ADN Células ARN Circular Pacientes Challenges and achievements of liquid biopsy technologies employed in early breast cancer